Impact of body mass index (BMI) on the efficacy of zoledronic acid in premenopausal patients with hormone receptor positive breast cancer: An analysis of the ABCSG-12 trial.
Georg Pfeiler(Medical University of Vienna), Michael Gnant(Austrian Breast & Colorectal Cancer Study Group), Vesna Bjelic‐Radisic(Helios Universitätsklinikum Wuppertal), Christian Marth(Nordic Society of Gynecologic Oncology), Guenther G. Steger(Mount Vernon Hospital), Christian Fesl(Austrian Breast & Colorectal Cancer Study Group), Richard Greil(Paracelsus Medical University), Robert Königsberg(Kaiser-Franz-Josef-Spital), Peter Dubsky(Hirslanden Klinik St. Anna), Brigitte Mlineritsch(Paracelsus Medical University), Michael Seifert(Zimmer Biomet (Germany)), Hellmut Samonigg(Graz University Hospital), Herbert Stöger(Medical University of Graz), S. Poestlberger, R. Jakesz(Comprehensive Cancer Center Vienna), Christian F. Singer(Comprehensive Cancer Center Vienna)
Cited by 2
Related Papers
Breast cancer
|Nature Reviews Disease Primers|2019|2.9k
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
|New England Journal of Medicine|2016|2.5k
Breast cancer
|The Lancet|2016|2.3k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study
|Journal of Clinical Oncology|2010|1.6k